Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • SC-DARIC33

    - PMLiVE

    ICR researchers identify potential treatment approach for acute myeloid leukaemia

    More than 3,100 people are diagnosed with the aggressive blood cancer in the UK every year

    Daiichi Sankyo logo

    Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia

    Approximately 18,000 cases of the blood cancer are diagnosed every year in Europe

    - PMLiVE

    UK scientists reveal promising new treatment strategy for acute myeloid leukaemia

    The aggressive form of blood cancer is responsible for more than 3,000 new cases in the UK every year

    - PMLiVE

    Bristol Myers Squibb to acquire Orum’s experimental blood cancer therapy for up to $180m

    ORM-6151 has been cleared for early-stage testing in AML or myelodysplastic syndromes

    - PMLiVE

    2Seventy bio’s partner pauses phase 1 leukaemia study following patient death

    The death occurred in the first patient treated with the CAR-T cell therapy at the second dosing level

    - PMLiVE

    BMS and 2seventy bio report positive phase 3 results for multiple myeloma treatment

    An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

    - PMLiVE

    FDA approves Rigel’s Rezlidhia for acute myeloid leukaemia

    Phase 2 data showed a complete remission rate of 35% and median duration of 25.9 months

    - PMLiVE

    Bristol Myers Squibb’s acute myeloid leukaemia oral maintenance therapy recommended by NICE

    Phase 3 trial results show Onureg offers significantly longer overall and relapse-free survival

    - PMLiVE

    EMA accepts Otsuka and Astex’s marketing authorisation application for acute myeloid leukaemia treatment 

    The application is supported by results from a phase 3 trial demonstrating an exposure equivalence to the current standard of care for AML

    - PMLiVE

    BMS and 2seventy bio announce positive results for multiple myeloma treatment

    The results show that Abecma ‘significantly improves’ progression-free survival in relapsed and refractory multiple myeloma

    - PMLiVE

    FDA lifts hold on Gilead’s clinical trials for leukaemia

    Following a review of the safety data, enrolment can be resumed for the MDS and AML clinical trials

    - PMLiVE

    BMS and 2seventy bio move away from CAR-T programme

    The two companies will focus their efforts on furthering the growing success of BMS’ therapy Abecma

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links